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ABSTRACT
Tetraspanins are believed to interact with specific partner proteins forming 
tetraspanin-enriched microdomains and regulate some aspects of partner protein 
functions. However, the role of Tspan5 during pathological processes, particularly 
in cancer biology, remains unknown. Here we report that Tspan5 is significantly 
downregulated in gastric cancer (GC) and closely associated with clinicopathological 
features including tumour size and TNM stage. The expression of Tspan5 is inversely 
correlated with patient overall survival and is an independent prognostic factor in 
GC. Upregulation of Tspan5 in tumour cells results in inhibition of cell proliferation 
and colony formation in vitro and suppression of xenograft growth of GC by reducing 
tumour cell proliferation in vivo. Thus, Tspan5 functions as a tumour suppressor 
in stomach to control the tumour growth. Mechanistically, Tspan5 inhibits the cell 
cycle transition from G1-S phase by increasing the expression of p27 and p15 and 
decreasing the expression of cyclin D1, CDK4, pRB and E2F1. The correlation of Tspan5 
expression with the expression of p27, p15, cyclin D1, CDK4, pRB and E2F1 in vivo are 
also revealed in xenografted tumours. Reconstitution of either cyclin D1 or CDK4 in 
Tspan5-overexpressing GC cells rescues the inhibitory phenotype produced by Tspan5, 
suggesting that cyclin D1/CDK4 play a dominant role in mediating the suppression 
of tumour growth by Tspan5 in GC. Our results suggest that Tspan5 may serve as a 
prognostic biomarker for predicting outcome of GC patients and provide new insights 
into the pathogenesis of GC and rational for the development of clinical intervention 
strategies against GC.
INTRODUCTION
Gastric adenocarcinoma (gastric cancer, GC) is the 
fifth most common malignant disease and third leading 
cause of cancer-related mortality worldwide [1]. However, 
in China GC is currently the second most common cancer 
and second leading cause of cancer death [2]. A total of 
679,100 new stomach cancer cases and 498,000 deaths 
are estimated in 2015, accounting for 15.8% of the total 
estimated cancer cases and 17.7% of total estimated deaths 
in China [2]. Although both diagnosis and treatment 
have been improved [3, 4], overall 5-year survival only 
ranges from 5-20% with the best median overall survival 
of 13.8 months so far [5]. The tumour-node-metastasis 
(TNM) classification is the most widely used staging 
system for prognosis of GC patients, but it is difficult 
to obtain precise prognostic information [6]. Therefore, 
identification of new targets will help us to understand 
the molecular mechanisms of pathogenesis and to develop 
novel targeted therapies or biomarkers for evaluating the 
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therapeutic efficacy or predicting the outcome of GC 
patients [7].
Tetraspanins are evolutionarily conserved small 
proteins of 204-355 amino acids (20–50kDa) that are 
characterized by four conserved transmembrane (TM) 
domains, short cytoplasmic amino- and carboxyl-terminal 
tails, a short intracellular loop, a small extracellular 
loop, and a large extracellular loop [8]. Tetraspanins 
typically organize laterally with specific partner proteins 
to form tetraspanin-enriched microdomains (TEMs) via 
tetraspanin-tetraspanin interactions [9, 10]. Within TEMs, 
tetraspanins are believed to coordinate some aspects of 
partner protein functions, particularly those of receptor 
tyrosine kinases (eg EGFR and c-Met), regulating cell 
adhesion, migration, invasion, signaling, cell-cell 
fusion, infection by cancer-causing viruses, morphology 
and survival during physiological and pathological 
processes [8, 11, 12]. Total 33 members in the tetraspanin 
superfamily have been identified in humans, but only 
a limited number of members have so far been studied 
in mammalian cells. Some members such as Tspan24 
(CD151), Tspan28 (CD81), Tspan29 (CD9) and Tspan30 
(CD63) have a wide cell and tissue distribution while 
others such as Tspan20 (UP1b), Tspan21 (UP1a), Tspan22 
(RDS), Tspan23 (ROM1), Tspan25 (CD53) and Tspan26 
(CD37) show a more restricted pattern of expression [11, 
13]. It has been reported that many tetraspanins such as 
Tspan1 (NET-1), Tspan8 (CO-029), Tspan13 (NET-6), 
Tspan24 (CD151), Tspan27 (CD82), Tspan28 (CD81), 
Tspan29 (CD9) and Tspan30 (CD63) were deregulated 
in various types of human cancers, implying that these 
tetraspanins may be involved in tumourigenesis and/or 
tumour progression [11–17]. In contrast, little has been 
known about Tspan5 (NET-4, TMS4SF9). Tspan5 was 
reported to highly express in brain cortical structures 
including the hippocampus, amygdala and in Purkinje 
cells, and parallel neuronal maturation in cerebellum 
of mice [18, 19]. Such expression pattern suggests 
that Tspan5 might be involved in both developmental 
and functional maturation of the brain [20]. It was 
reported that osteoclastogenic RANKL signaling could 
increase Tspan5 expression in osteoclast precursor cells 
[21] and knockdown of Tspan5 expression inhibited 
osteoclastogenesis [22], suggesting the role of Tspan5 
in osteoclast formation and osteoclast differentiation. 
However, whether Tspan5 has a role in tumourigenesis is 
unknown.
We are interested in the role of Tspan5 in cancer 
biology and clinical significance. In this study, we 
report that Tspan5 was downregulated in GC and 
closely associated with clinicopathological features. The 
expression of Tspan5 was inversely correlated with patient 
overall survival and was an independent prognostic factor 
in GC. Upregulation of Tspan5 expression demonstrated 
that Tspan5 functions as a tumour suppressor to inhibit 
cell proliferation in vitro and xenograft growth in vivo. 
The underlying molecular mechanisms were unveiled 
to control the cell cycle transition from G1-S phase by 
regulating the activity in the molecular pathway of p27/
cyclin D1/CDK4/pRB/E2F1 in GC.
RESULTS
Downregulation and association of Tspan5 with 
clinicopathological feature of GC
We determined the protein level of Tspan5 by 
immunohistochemical staining (IHC) of a cohort of 114 
pairs of tumour tissues and adjacent non-tumour tissues. 
Tspan5 was strongly expressed in adjacent tissues but 
weakly expressed in tumour tissues, predominantly 
located on membrane and in cytoplasm of the para-
neoplastic cells (Figure 1AB). Quantitative analysis by 
scoring the staining (Figure 1C) revealed that Tspan5 
was significantly downregulated in tumour tissues 
versus in adjacent non-tumour tissues (4.51±2.61 
versus 9.66±2.30, P<0.001). Based on staining scores, 
we divided the cohort patients into low expression 
group (N=55) and high expression group (N=59) 
respectively to investigate if the expression level of 
Tspan5 is associated with clinicopathological features. 
Interestingly, decreased expression of Tspan5 was 
significantly associated with tumour size (P<0.001), 
tumour invasive depth (P<0.05), lymph node metastasis 
(P<0.05) and TNM stage (P<0.01) (Table 1). However, 
Tspan5 expression did not appear to be associated with 
age, gender, tumour location and differentiation. Thus, 
the results suggest that decreased expression of Tspan5 
may be involved in the pathogenesis of GC.
Correlation of Tspan5 expression with overall 
survival of GC patients
Kaplan-Meier survival analysis showed that low 
expression of Tspan5 in GC was highly correlated with 
overall survival of all GC patients (P<0.001) (Figure 
1D) or stratified patients with TNM stage I+II (P<0.001) 
and with TNM stage III+IV (P<0.01) (Figure 1E). 
Univariate Cox regression analysis demonstrated that 
many parameters including tumor size, invasion depth, 
lymph metastasis, tumour differentiation and TNM stage 
were significantly correlated with patient overall survival 
(P<0.05); however, others including age, gender, and 
tumour location were not correlated with the overall 
survival (Table 2). Multivariate analysis revealed that 
Tspan5 expression was an independent prognostic 
factor for GC patients (HR 6.558, 95%CI 3.055–14.078, 
P<0.001). Thus, the results suggest that decreased 
expression of Tspan5 may increase tumour growth and 
progression while increased expression of Tspan5 is an 
independent favourable prognostic factor for GC.
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Figure 1: Tspan5 was downregulated in GC and correlated with clinicopathological features and patient overall 
survival. A. IHC analysis of Tspan5 expression in 114 pairs of tumour tissues and adjacent non-tumour tissues. Representatives of Tspan5 
staining intensity: (i) Strong in adjacent tissue, (ii) moderate in tumour tissue, (iii) weak in tumour tissue, and (iv) negative in tumour tissue. 
200× magnifications, scale bar 40μm. B. The expression of Tspan5 was associated with GC staging. (i) Strong in adjacent normal tissue, 
(ii) moderate in TNM stage II, (iii) weak in TNM stage III, and (iv) negative in TNM stage IV. Upper panels: 200× magnifications, scale 
bar 40μm.; lower panels: 400× magnifications, scale bar 20μm. C. The expression of Tspan5 in 114 pairs of GC was significantly higher 
in tumour tissues than that of adjacent normal tissues (4.51±2.61 versus 9.66±2.30, Student’s t-test, ***P<0.001). D. The expression of 
Tspan5 was inversely correlated with overall survival of all 60 GC patients (***P<0.001) as revealed by Kaplan–Meier analysis. E. The 
expression of Tspan5 was inversely correlated with overall survival of 23 patients with TNM stage I+II group (***P<0.001) or that of 37 
patients with TNM stage III+IV group (**P<0.01) as shown by Kaplan–Meier analysis.
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Tspan5 inhibited GC proliferation, colony 
formation and migration in vitro
To investigate the role of Tspan5 in pathogenesis 
of GC in vitro, we up-regulated Tspan5 expression 
in tumour cells by retrovirus-mediated transduction. 
Western blotting confirmed that Tspan5 was significantly 
upregulated in either AGS or MKN45 cells compared to 
empty vector-containing retrovirus control (Figure 2A). 
CCK-8 proliferation assays showed that Tspan5 inhibited 
cell proliferation of either AGS or MKN45 compared to 
relative control (Figure 2B). Colony formation assays 
demonstrated that Tspan5 significantly reduced the 
numbers of colony formed by either AGS or MKN45 cells 
(P<0.001) (Figure 2C). Boyden chamber migration assays 
showed that Tspan5 dramatically inhibited the migration 
of AGS and MKN45 toward the bottom chamber (both 
P<0.001) (Figure 2D). Consistent with the Boyden 
chamber results, similar results were also obtained from 
wound healing assays for either AGS or MKN45 cells 
(P<0.01) (Figure 2E). Thus, the results suggest that 
Tspan5 may act as a tumour suppressor to control tumour 
growth and progression of GC in vitro.
Tspan5 suppressed tumor growth in vivo
To investigate whether Tspan5 affects tumour 
growth in vivo, we subcutaneously implanted Tspan5-
overexpressing or control AGS cells into BALB/c nude 
mice [23]. Twenty days later, the animals were sacrificed 
and their tumours were harvested. As shown in Figure 3A, 
upregulation of Tspan5 significantly inhibited the tumor 
growth in vivo. Tumour volume of Tspan5-overexpressing 
cells was about 9-fold less than that of control cells on 
day 20 (84.17±7.39 versus 746.40±57.15, P<0.001). IHC 
staining of tumour sections confirmed the upregulation of 
Tspan5 in tumour cells compared to the control (P<0.001). 
Tumour cell proliferation was significantly decreased in 
the Tspan5-overexpressiing group versus in the control 
group (P<0.001), as revealed by Ki67 staining, whereas 
tumour cell apoptosis did not appear to have any difference 
between the two groups (P>0.05), as demonstrated by 
Table 1: Association of Tspan5 expression with clinicopathological characteristics of 114 gastric cancer patients (*χ2-
test)
Characteristics No. of Case Expression of Tspan5 P value*
Low High
Age
 ≥61
 <61
74
40
37 (50%)
18 (45%)
37 (50%)
22 (55%)
0.610
Gender
 Male
 Female
89
25
42 (47%)
13 (52%)
47 (53%)
12 (48%)
0.671
Tumour size (cm)
 ≥6
 <6
52
62
38 (73%)
17 (27%)
14 (27%)
45 (73%)
0.000
Location
 Cardiac
 Corpus
 Antrum
22
44
48
7 (32%)
27 (61%)
21 (44%)
15 (68%)
17 (39%)
27 (56%)
0.055
Invasive depth
 T1+T2
 T3+T4
21
93
6 (29%)
49 (53%)
15 (71%)
44 (47%)
0.046
Lymph node metastasis
 No
 Yes
36
78
12 (33%)
43 (55%)
24 (67%)
35 (45%)
0.030
TNM stage
 I+II
 III+IV
52
62
18 (35%)
37 (60%)
34 (65%)
25 (40%)
0.008
Differentiation
 Well/moderate
 Poor
28
86
10 (36%)
45 (52%)
18 (64%)
41 (48%)
0.127
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activated-caspase 3 staining (Figure 3B). Thus, the results 
confirm that Tspan5 functions as a tumour suppressor to 
inhibit tumour growth of GC in vivo.
Tspan5 regulated cell cycle transition from G1-S 
phase by increasing p27/p15 and decreasing 
cyclin D1/CDK4/pRB/E2F1
Cell cycle analysis showed that Tspan5-
overexpressing AGS cells exhibited significant increased 
percentage of cells in G1/G0 compared to that of control 
cells (44.95±0.65 versus 50.14±2.89, P<0.05) (Figure 
4A). Consistently, increased percentage of cells in G1/
G0 phase by Tspan5 was also observed in MKN45 cells 
(51.82±2.89 versus 58.05±2.20, P<0.05). No significant 
difference for tumour cell apoptosis was observed between 
Tspan5-overexpressing cells and control cells in either 
AGS (4.61±1.22 versus 5.04±0.59, P=0.521) or MKN45 
(8.87±0.71 versus 9.03±0.89, P=0.812) (Supplementary 
Figure). Thus, the results suggest that Tspan5 controls the 
cell cycle transition from G1-S phase.
We then focused on the molecular mechanisms in 
which Tspan5 postpones the G1-S transition by analyzing 
the expression of G1/S checkpoint proteins. Western 
blotting showed that upregulation of Tspan5 increased the 
expression of p27 and p15 but decreased the expression 
of cyclin D1, CDK4, pRB and E2F1, compared to each 
control, in both AGS and MNK45 cell lines (Figure 4B). 
To verify the in vitro results, we further investigated the 
expression of cyclin D1, CDK4, p27, p15, pRB and E2F1 
in vivo. IHC staining demonstrated that upregulation of 
Tspan5 significantly increased the expression of p27 and 
p15 but dramatically decreased the expression of cyclin 
D1, CDK4, pRB and E2F1 in xenograft tumours compared 
to control tumours (all P<0.001, Figure 4C). Consistent 
with these results, Pearson correlation analysis revealed 
that the expression of Tspan5 was positively correlated 
with the expression of p27 (r= 0.952, P<0.001) and p15 
(r= 0.930, P<0.001), but reversely correlated with the 
expression of cyclin D1 (r= – 0.965, P<0.001), CDK4 (r= 
– 0.914, P<0.001), E2F1 (r= – 0.912, P<0.001) and pRB 
(r= – 0.894, P<0.001) in vivo (Figure 4D).
Restitution of CDK4 and cyclin D1 rescued the 
phenotype produced by Tspan5
We reconstituted CDK4 in Tspan5-overexpressing 
tumour cells by transfecting the pCMV-Myc-CDK4 
construct and confirmed the upregulation of CDK4 in 
tumour cells by Western blotting (Figure 5A). After 48 
hours, we assessed cell proliferation in vitro by using 
CCK-8 assays. For either AGS or MNK45 cell lines, the 
proliferation of Tspan5+CDK4 cells was significantly 
increased as compared to both controls of Tspan5+Control 
and Tspan5 (P<0.001) as well as the basal control 
(P<0.01, Figure 5B). We then reconstituted cyclin D1 in 
Tspan5-overexpressing tumour cells by transfection with 
the pENTER-cyclin D1 expression vector (Figure 5C). 
Similarly, the proliferation of Tspan5+cyclin D1 cells was 
significantly increased as compared to Tspan5+Control, 
Tspan5 control or the basal control for both AGS and 
MKN4 cell lines (P<0.01, Figure 5D). Together, the 
results suggest that reconstitution of either CDK4 or cyclin 
D1 rescues the inhibitory phenotype produced by Tspan5, 
supporting further that Tspan5 suppresses the tumour 
growth of GC by control of the cell cycle transition from 
G1-S phase via decreasing the expression of CDK4 and 
cyclin D1.
Table 2: Univariate and multivariate analysis of potential prognostic factors in 60 gastric cancer patients (HR: 
hazard ratio and CI confidence interval)
Factors No of case Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95%CI) P value
Age (≥61/<61) 42/18 0.886 (0.448–1.751) 0.727
Gender (male/female) 49/11 1.061 (0.468–2.406) 0.886
Tumour size (≥6/<6 cm) 31/29 2.024 (1.06–3.867) 0.033 0.417
Location (Cardiac/Corpus/
Antrum)
10/28/22
1.121 (0.446–2.815)
1.059 (0.522–2.146)
0.809
0.874
Invasive depth (T1+T2/T3+T4) 9/51 0.204 (0.049–0.851) 0.029 0.456
Lymph node metastasis (No/Yes) 17/43 0.426 (0.187–0.969) 0.042 0.389
TNM stage (I+II/III+IV) 23/37 0.357 (0.172–0.738) 0.005 0.751
Differentiation (poor/well/
moderate) 47/13 2.684 (1.044–6.897) 0.040 0.161
Tspan5 expression (low /high) 32/28 6.558 (3.055–14.078) 0.000 6.558 (3.055-14.078) 0.000
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Figure 2: Upregulation of Tspan5 expression inhibited GC proliferation, colony formation and migration in vitro. A. 
Western blotting confirmed the upregulation of Tspan5 in both AGS and NKN45 cell lines. AGS/Tspan5 and MKN45/Tspan5 were the AGS 
and MKN45 cell lines transduced with Tspan5 vector-containing retrovirus; AGS/Control, MKN45/Control were the AGS and MKN45 
cell lines transduced with empty vector-containing retrovirus. B. CCK-8 proliferarion assays showing the proliferation inhibition of either 
AGS (upper panel) or MKN45 (lower panel) by Tspan5 over 4-day culture (Student’s t-test, all *P<0.05). C. Colony formation assays 
showing a significant decrease of the numbers of cell colony by Tspan5 in either AGS cells (left panel) or MKN cells (right panel) (Student’s 
t-test, ***P<0.001). D. Boyden chamber migration assays showing a significant decrease of GC migration by Tspan5 in either AGS cells 
(upper panels) or MKN cells (lower panels) (Student’s t-test, ***P<0.001). E. Wound healing assays showing a significant decrease of GC 
migration by Tspan5 in either AGS cells (left) or MKN cells (right) (Student’s t-test, **P<0.01).
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DISCUSSION
In this study, we demonstrated for the first time 
that the expression of Tspan5 is downregulated GC 
tumour tissues compared to adjacent non-tumour tissues. 
Remarkably, the expression of Tspan5 is closely associated 
with some clinicopathological features including tumour 
size, invasive depth, lymph node metastasis and TNM 
stage and inversely correlated with overall survival of 
GC patients. Multivariate analysis revealed that increased 
expression of Tspan5 is an independent favourable 
prognostic factor for predicting patient outcome in GC. 
Our findings suggest that decreased expression of Tspan5 
may be involved in the pathogenesis of GC.
To investigate the role of Tspan5 in the pathogenesis 
of GC, we upregulated the expression of Tspan5 in GC 
cells by retrovirus-mediated transduction. We found 
that Tspan5 significantly inhibited the growth, colony 
formation and migration of GC cells in vitro. More 
importantly, upregulation of Tspan5 dramatically 
decreased the tumour growth in vivo by reducing tumour 
cell proliferation. Taken together, we conclude that Tspan5 
functions as a tumour suppressor in stomach to control the 
tumour growth of GC.
Many tumour suppressors constrain cell growth and 
proliferation by regulating various signalling pathways that 
impinge the core cell cycle machinery [24, 25]. To study 
underlying cellular mechanisms, we performed cell cycle 
Figure 3: Tspan5 suppressed tumour growth of GC in vivo. A. Upregulation of Tspan5 expression in AGS cells suppressed 
the tumour growth of GC in vivo (Student’s t-test, *P<0.05, **P<0.01, ***P<0.001). B. IHC staining showing increased expression of 
Tspan5 but decreased expression of Ki67 in Tspan5-overexpressing tumours versus that of contro tumours (Student’s t-test, ***P<0.001). 
However, there was no difference of the expression of active caspase 3 between Tspan5-tumour and control tumour (NS, P>0.05). 200× 
magnifications, scale bar 40μm.
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Figure 4: Tspan5 regulated cell cycle transition from G1-S phase by increasing p15/p27 and decreasing cyclin D1/
CDK4/pRB/E2F1. A. Flow-cytometry analysis of the cell cycle progression showing an increase of the percentage of cells in G0/G1 
phase of Tspan5-overexpressing GC compared to that of control cells in both AGS and MKN45 cell lines (Student’s t-test, *P<0.05). B. 
Western blotting showing the alternation of the expression of cyclin D1, CDK4, p27, p15, E2F1 and pRB in both AGS and MKN45 cell lines 
by Tspan5. C. IHC staining showing the increased expression of p27 and p15 and the decreased expression of cyclin D1, CDK4, E2F1 and 
pRB in Tspan5-overexpressing tumours versus control tumours (Student’s t-test, N=6, ***P<0.001). 200× magnifications, scale bar 40μm. 
(Continued )
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Figure 4 (Continued ): D. Pearson correlation analysis for the correlation of Tspan5 expression with the expression of cyclin D1, CDK4, 
p27, p15, E2F1 or pRB in xenografted tumours (N=12, all ***P<0.001).
Figure 5: Restitution of CDK4 and cyclin D1 rescued the phenotype produced by Tspan5. A. Reconstitution of CDK4 in 
Tspan5-overexpressing (Tspan5) or control (Control) tumour cells by transfecting pCMV-Myc-CDK4 into either AGS or MKN45 cells. 
Western blotting confirming the downregulation of CDK4 by Tspan5 (Tspan5 versus Control) and the upregulation of CDK4 (Tspan5+CDK4 
versus Tspan5+Control) in both Tspan5-overexpressing AGS and MKN45 cell lines. B. CCK-8 proliferation assays showing the increased 
proliferation of both AGS and MKN45 cells after 48 hours by reconstitution of CDK4 in Tspan5-overexpressing cells (ANOVA test, 
**P<0.001 or ***P<0.001). C. Reconstitution of cyclin D1 in Tspan5-overexpressing (Tspan5) or control (Control) tumour cells by 
transfecting pENTER-cyclin D1 into either AGS or MKN45 cells. Western blotting confirming the downregulation of cyclin D1 by Tspan5 
(Tspan5 versus Control) and the upregulation of cyclin D1 (Tspan5+CycD1 versus Tspan5+Control) in both Tspan5-overexpressing AGS 
and MKN45 cell lines. D. CCK-8 proliferation assays showing the increased proliferation of both AGS and MKN45 cells after 48 hours by 
reconstitution of cyclin D1 in Tspan5-overexpressing cells (ANOVA test, **P<0.001 or ***P<0.001).
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analysis by flow-cytometry. We found that upregulation of 
Tspan5 significantly increase the percentage of cells in G1/
G0 phase but not in S phase and G2/M phase, suggesting 
that Tspan5 regulates the cell cycle transition from G1-S 
phase of GC. Deregulation of signalling networks during 
G1 phase of the cell cycle represents a major driving 
force in tumourigenesis and development of cancer [25]. 
Cyclin D1 is the first cyclin expressed in G1 phase in 
response to numerous mitogenic signals and peaks in 
mid-G1. Cyclin D1 interacts with CDK4 to form active 
cyclin D1/CDK4 complex that translocate to the nucleus 
and phosphorylate the tumour suppressor retinoblastoma 
(pRB). This phosphorylation leads to the release of pRB 
from its binding partners E2F family proteins and thus 
activates the transcription of E2F-dependent genes that 
are required for the G1-S phase transition and for the 
initiation of DNA replication at the late G1 [25, 26]. One 
mechanism that regulates the cell cycle transition from 
G1-S phase relies on CDK inhibitory proteins (CDKIs) 
such as p27Kip and p15Ink4b that latch onto the cyclin D1/
CDK4 complex and inhibit the kinase activity [25, 27]. 
Therefore, CDKI, cyclin D1, CDK4, pRB and E2F 
encompass the central players in the cell cycle transition 
from G1-S phase [25, 28, 29]. To explore molecular 
mechanisms underlying the effect of Tspan5 on the cell 
cycle progression, we focused on the CDKI/cyclin D1/
CDK4/pRB/E2F1 pathway. We found that upregulation of 
Tspan5 significantly increases the expression of p27 and 
p15 but decreases the expression of cyclin D1, CDK4, 
pRB and E2F1 in both AGS and MNK45 cell lines. 
More importantly, either upregulation of p15 and p27 
or downregulation of cyclin D1, CDK4, pRB and E2F1 
in tumour cells were also found in xenografted tumours 
of GC. Such upregulation or downregulation was highly 
correlated with the upregulation of Tspan5 in vivo. Indeed, 
upregulation of cyclin D1 and CDK4 has been found in 
clinical samples of GC [30, 31]. To corroborate the role 
of cyclin D1 and CDK4 in the suppression of tumour 
growth of GC by Tspan5, we reconstituted the expression 
of cyclin D1 and CDK4 in Tspan5-overexpressing tumour 
cells. We found that either cyclin D1 or CDK4 could not 
only reverse the inhibitory phenotype produced by Tspan5 
but also promote the cell growth further as compared to 
the basal control, suggesting that cyclin D1/CDK4 have 
a dominant role in mediating the suppression of tumour 
growth by Tspan5 in GC.
It has been noted that TspanC8 subgroup of 
tetraspanins, consisting of Tspan5, Tspan10, Tspan14, 
Tspan15, Tspan17 and Tspan33, all six of which contain 
8 cysteine residues within their main extracellular 
region [32, 33], were recently found to interact with a 
disintegrin and metalloprotease 10 (ADAM10), regulate 
the maturation and trafficking of ADAM10 to the cell 
surface [32–34], and increase the cleavage of various 
ADAM10 substrates, Notch signaling and ADAM10 
membrane compartmentalization in multiple cell types 
and species [22, 32, 33, 35, 36]. In fact, ADAM10 is 
able to cleave the extracellular regions of more than 
40 different transmembrane targets, including Notch 
receptors, amyloid precursor protein APP, chemokines 
CX3CL1 and CXCL16, growth factor receptors EGFR 
and VEGFR2, and various adhesion proteins [37, 38]. 
There is evidence that different TspanC8 proteins can 
promote ADAM10 shedding of specific substrates and 
thus impact on its substrate selectivity in different cell 
types [33, 36, 39]. All such information might provide 
some clues to further understand how Tspan5 would 
regulate the cell cycle transition from G1-S phase in 
gastric tumour. Clearly, whether Tspan5 could interact 
with ADAM10, increase the cleavage of its substrates 
such as Notch and EGFR, and thus regulate the activity 
of CDKI/cyclin D1/CDK4/pRB/E2F1 pathway warrants 
further investigation in future.
In conclusion, we have demonstrated that Tspan5 
is downregulated in tumour tissue and inversely 
correlated with clinicopathological features and overall 
survival of GC patients. Increased expression of Tspan5 
serves as an independent favourable prognostic factor 
for predicting the outcome of GC patients. Tspan5 
decreases cell proliferation and colony formation in 
vitro and suppresses the xenograft growth of GC in 
vivo. Thus, Tspan5 functions as a tumour suppressor 
in stomach to control the tumour growth of GC. 
Mechanistically, Tspan5 suppresses the tumour growth 
through regulating the cell cycle transition from G1-S 
phase by increasing the expression of p27 and p15 and 
decreasing the expression of cyclin D1, CDK4, pRB 
and E2F1. Our findings provide new insights into the 
pathogenesis of GC and rational for the development of 
clinical intervention strategies against GC.
MATERIALS AND METHODS
Cell lines and cell culture
Human gastric cancer cell lines AGS and MKN45 
were purchased from the Typical Culture Preservation 
Commission Cell Bank (Chinese Academy of Sciences, 
Shanghai, China). All cell lines were cultured in RPMI 
1640 medium (Hyclone, USA) supplemented with 10% 
fetal bovine serum (FBS) (Gibco, UK) and maintained at 
37°C with 5% CO
2
.
Patients and clinical tissue specimens
A cohort of 114 pairs of GC tumour tissues and 
matched adjacent non-tumour tissues on tissue microarray 
(TMA) chips containing pathological and clinical 
information were purchased from Shanghai Outdo Biotech 
Co., Ltd (Shanghai, China). Patients’ consent and approval 
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from local Ethics Committee were obtained for only 
research purpose in use of these human clinical materials. 
There are 89 males and 25 females (mean age of 65 years 
old, ranging from 40–87 years old). All clinical samples 
are categorized into age, gender, tumour size, tumour 
location, invasive depth, lymph node metastasis, TNM 
stage, differentiation status, and patient survival time.
Immunohistochemistry (IHC) and scoring
IHC staining was done with the IHC kit as described 
previously [40]. Briefly, the TMAs were roasted for 
3 h at 65°C, deparaffinized and rehydrated through 
dimethylbenzene and graded alcohols, and then rinsed in 
tap water for few seconds. Endogenous peroxidase was 
blocked with 3% hydrogen peroxide for 15 min at room 
temperature. After rinsed in 0.01 M phosphate-buffered 
saline solution (PBS) for (3×3 min), the slides were then 
exposed to the antigen retrieval system (10 mM sodium 
citrate, pH6.0) in a microwave oven for 20 min. To 
minimize non-specific staining, the TMAs were blocked 
in 10 % normal goat serum for 30 min and then incubated 
with rabbit primary antibody anti-Tspan5 (1:600; Sigma-
Aldrich, St. Louis, USA) for 2 h at room temperature. 
After washed in PBS (3×3 min), the slides were incubated 
with horseradish peroxidase (HRP)-labeled anti-rabbit 
secondary antibody (Gene Tech, Shanghai, China) for 
30 min at room temperature and then reacted with DAB 
working solution (1:50; GeneTech, Shanghai, China). 
Hematoxylin staining was performed on the TMAs for 
5 min. Histopathological features of stained tissues were 
evaluated and scored separately by two pathologists 
who blinded to the pathological information and patient 
clinical data. The intensity of Tspan5 staining was scored 
as negative (0), weak (1), moderate (2) and strong (3). The 
extent of Tspan5 staining was defined as the percentage of 
positive stained cells: 1 (<10%), 2 (10–50%), 3 (51–80%), 
and 4 (>80%). The final expression scores for statistical 
analysis were the product of the score of intensity and that 
of extent. The expression level of Tspan5 was considered 
high if the final score was ≥4 or low if the final score was 
<4 [40].
Xenograft tumours were also sectioned (3-4μm per 
section). Primary antibodies used for xenograft tumour 
staining were against Ki67 (1:400), active caspase 3 
(1:2000), p15 (1:50), p27 (1:50), cyclin D1 (1:50), CDK4 
(1:800), pRB (Ser807/811) (1:100) and E2F1 (1:50). Anti-
E2F1 antibody was purchased from Bioworld Technology 
(USA) and others purchased from Cell Signaling 
Technology (USA).
Expression vector construction and lentivirus 
transduction
Primers were designed to amplify the coding region 
of TSPAN5 gene (NM_005723): forward 5′-CCGCTC
GAGGCCACCATGTCCGGGAAGCACTACAAG-3′ 
and reverse 5′-CGCGGATCCCTACCAGCTCGCCCTG
ACAGCTTCGAT-3′. The pLNCX2-Tspan5 expression 
vector was constructed and verified by sequencing the 
inserted sequence. Either pLNCX2-Tspan5 or pLNCX2 
empty vector was transfected into the packaging cell line 
GP2-293 with Lipofectamine 2000 (Invitrogen, USA) as 
described previously [40]. After 72 hours, 1 ml of viral 
supernatant was collected and, plus 4µg/ml of polybrene, 
added to AGS or MKN45 cells for stable transduction. 
After G418 selection (1mg/ml) for 14 days, drug-resistant 
cell pools were established and the protein level of Tspan5 
was detected by Western blotting.
Western blotting
Protein extractions and Western blotting were 
performed as described previously [40]. Primary 
antibodies include anti-Tspan5 (1:3000; Sigma-Aldrich) 
and those contained in Cell Cycle Regulation Samper Kit 
½ [p15Ink4b, p27Kip, cyclin D1, CDK4, pRB (Ser807/811) 
and E2F1] (all 1:1000; Cell Signaling Technology, USA). 
GAPDH was used as a loading control to normalize the 
protein signal. Each experiment was repeated at least for 
three times.
Cell proliferation assays
Cell proliferation assays were performed using 
the Cell Counting Kit-8 (CCK-8) (Dojindo, Kumamoto, 
Japan) according to the manufacturer’s instruction. Briefly, 
a total of 5×103 cells in 1ml were in triplicate seeded in 
24-well plates and cultured at 37oC with 5% CO
2
 for one 
to 4 days. 20µl CCK-8 solution was added per well. After 
incubated at 37°C for 4 hours, absorbance at 450 nm was 
measured on a microplate reader (Bio-Rad). Each group 
was plated in three duplicate wells. Each experiment was 
repeated at least for three times.
Cell cycle analysis
Approximately 1×106 cells were trypsinized, washed 
twice with PBS, and fixed in ice-cold 70% ethanol for 
1 hour. The samples were then centrifuged to remove 
the ethanol and exposed to 100µl RNaseA (keyGEN 
BioTECH, Nanjing, China) for 30 min at 37°C. Cellular 
DNA was stained with 25μg/ml propidium iodide (PI) 
(Sigma, USA). Cell cycle distributions were determined 
by flow-cytometry.
Cell apoptosis assays
Approximately 1×106 cells were harvested and 
stained with Annexin V-APC and PI according to the 
manufacturer’s instructions (keyGEN BioTECH). Annexin 
V-APC/PI binding was analyzed by flow-cytometry using 
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a BD FACSCalibur system. The data were analyzed using 
CellQuest software.
Cell migration assays
Cell migration potential in vitro was measured 
using Boyden transwell chambers (8-µm pore, Corning 
star, Cambridge, USA). Cells in serum-free medium 
(5×104 cells/200µl) were added to the upper chambers 
of transwell plates. Then 10% FBS-containing medium 
was added to the lower chambers as a chemoattractant. 
After incubation at 37°C for 24 hours, those cells that have 
migrated and stuck to the lower surface of the membrane 
were fixed with methanol and stained with 0.1 % crystal 
violet. For quantification, cells were counted under a 
microscope in five randomly selected fields (original 
magnification, 200×). All assays were repeated at least for 
three times.
Wound healing assays
Wound healing assays were performed in 6-well 
plates (4×105 cells/well) in which a scratch was made at 
the centre of each well using a plastic tip (100μl size). 
All undetached cells were washed away with serum-free 
medium. Three randomly selected identical locations were 
imaged at 0 and 24 h under microscopy (200×) for each 
replicate. Results were expressed as the distance between 
the edges of individual wounds at 24 hours in compared 
with that of t=0 point; each group included three wells. 
The experiment was repeated for 3 times.
Colony formation assays
Cells in logarithmic growth phase were digested 
with 0.25% trypsin to acquire individual cells, which 
were suspended in RPMI 1640 medium containing 10% 
FBS. Cell suspensions of each group were diluted to 1000 
cells per well (6-well plates) and cultured at 37°C with 5% 
CO
2
 for 2–3 weeks. When colonies became visible with 
the naked eye, the medium in culture wells was removed. 
Paraformaldehyde (4%) was added to fix cell colonies for 
5min. After discarded the paraformaldehyde, 0.1% crystal 
violet dye was added for 15min. The dye was rinsed away 
with water and dried at room temperature. Numbers of cell 
colony were counted for statistical analysis.
Tumour xenografts
BALB/c nude mice aged 5-6 weeks old were 
purchased from the Experimental Animal Centre of 
Southern Medical University and maintained under 
standard pathogen-free conditions. Tumour xenografts 
were performed as described previously [40]. 1x107 GC 
cells were subcutaneously implanted into the left or right 
flanks of nude mice (6 mice per group). Tumour growth 
was measured with calipers from day 7 to day 20 after 
tumour cell implantation. Tumour volume was calculated 
by the formula of LxW2xπ/6, where L stands for tumour 
length and W for tumour width [41]. All experimental 
procedures were performed according to the regulation of 
animal usage for scientific research of Southern Medical 
University.
Statistical analysis
All statistical analyses were performed using the 
SPSS 20.0 software (IBM Corp., Armonk, NY). Student’s 
t-test, analysis of variance (ANOVA) or χ2-test were 
used as indicated in the results. All tests are two-sided. 
Kaplan–Meier analysis was used for analysis of overall 
survival data and Cox regression analysis for independent 
correlation of individual parameter with patient’s overall 
survival. Statistical significance was indicated in the 
results section by an asterisk where P<0.05, two asterisks 
where P<0.01, or three asterisks where P<0.001.
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SUPPLEMENTARY FIGURE
Supplementary Figure S1: Tspan5 did not affect the apoptosis of GC cells. Annexin V-APC and PI labeling apoptosis assays 
showed no significant difference for the percentage of apoptotic cells between Tspan5-overexpressig GC cells and the control cells of either 
AGS (upper panels: Student’s t-test, P=0.521) or MKN45 (lower panels: Student’s t-test, P=0.812).
Tspan5 is an independent favourable prognostic factor and 
suppresses tumour growth in gastric cancer
